ClinicalTrials.gg

Program

tegoprazan

Also written as “Tegoprazan”, “Tegoprazan 50 mg” and “BLI5100”.

Its studies are mostly in Esophagitis · Non-Erosive Reflux Disease · Gastroesophageal Reflux · Peptic Ulcer · Duodenal Ulcer, led by 4 companies.

Furthest: phase 4, since Mar 13, 202048 company-led studies, 7 open or runningNext primary completion: Jan 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HK inno.N376 open or runningphase 4since Mar 13, 2020Nov 14, 2011Jan 31, 2027phase 1 · NCT07853248
Shandong Luoxin Pharmaceutical Group Stock70 open or runningphase 3since Jul 9, 2018Jan 25, 2018none ahead
Sebela Pharmaceuticals30 open or runningphase 3since Oct 17, 2022Oct 17, 2022none ahead
Carnot Laboratories11 open or runningphase 4since May 20, 2025May 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 33 studies since Nov 14, 2011.

  1. Apr 25, 2022Phase 1 study in HealthyHK inno.N · NCT05353010 · 12 enrolled · Korea, Republic of
  2. Oct 9, 2022Phase 3 study in Helicobacter Pylori InfectionShandong Luoxin Pharmaceutical Group Stock · NCT05577468 · 561 enrolled · China
  3. Oct 17, 2022Sebela Pharmaceuticals's first studies: 2 phase 3 studiesNew to Sebela PharmaceuticalsSebela Pharmaceuticals · NCT05587322, NCT05587309
  4. Jan 18, 2023Phase 4 study in Gastroesophageal RefluxHK inno.N · NCT05701540 · 338 planned · Korea, Republic of
  5. Feb 2, 2023Phase 1 study in HealthyHK inno.N · NCT05723510 · 87 enrolled · Korea, Republic of
  6. May 5, 2023Phase 3 study in Non-Erosive Reflux DiseaseSebela Pharmaceuticals · NCT05890001 · 400 enrolled · United States
  7. May 10, 2023Phase 1 study in Healthy SubjectsShandong Luoxin Pharmaceutical Group Stock · NCT05883306 · 6 enrolled · China
  8. May 23, 2023Phase 2 study in Helicobacter Pylori InfectionHK inno.N · NCT05933031 · 381 planned · Korea, Republic of
  9. Jun 2, 2023Phase 1 study in HealthyShandong Luoxin Pharmaceutical Group Stock · NCT05915871 · 22 enrolled · China
  10. Dec 1, 2023Phase 1 study in HealthyHK inno.N · NCT06164834 · 48 planned · Korea, Republic of
  11. Feb 20, 2024Phase 1 study in HealthyHK inno.N · NCT06332638 · 36 planned · Korea, Republic of
  12. May 20, 2025Carnot Laboratories's first study: phase 4 study in Gastroesophageal RefluxNew to Carnot LaboratoriesCarnot Laboratories · NCT06991348 · 128 planned · Mexico
  13. Sep 13, 2026Phase 4 study in Gastroesophageal RefluxHK inno.N · NCT07826455 · 100 planned
  14. Sep 14, 2026Phase 1 study in Healthy Adult MaleHK inno.N · NCT07853248 · 34 planned · South Korea

Ahead

  1. Jan 31, 2027Primary completion: phase 1 study in Healthy Adult MaleHK inno.N · NCT07853248
  2. Jul 31, 2028Primary completion: phase 4 study in Gastroesophageal RefluxHK inno.N · NCT07826455

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 48 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07853248Healthy Adult Male · South Korea1Not yet recruitingHK inno.NJan 31, 202734
NCT07826455Gastroesophageal Reflux4Not yet recruitingHK inno.NJul 31, 2028100
NCT06991348Gastroesophageal Reflux · Mexico4RecruitingCarnot LaboratoriesNov 30, 2025128
NCT06332638Healthy · Korea, Republic of1By invitationHK inno.NJul 31, 202436
NCT06164834Healthy · Korea, Republic of1Not yet recruitingHK inno.NNov 202448
NCT05915871Healthy · China1CompletedShandong Luoxin Pharmaceutical Group StockApr 28, 202322
NCT05933031Helicobacter Pylori Infection · Korea, Republic of2RecruitingHK inno.NDec 31, 2024381
NCT05883306Healthy Subjects · China1CompletedShandong Luoxin Pharmaceutical Group StockJul 21, 20226
NCT05890001Non-Erosive Reflux Disease · United States3CompletedSebela PharmaceuticalsOct 8, 2024400
NCT05723510Healthy · Korea, Republic of1CompletedHK inno.NJul 17, 202387
NCT05701540Gastroesophageal Reflux · Korea, Republic of4RecruitingHK inno.NDec 31, 2024338
NCT05587322Non-Erosive Reflux Disease · United States3CompletedSebela PharmaceuticalsOct 13, 2023788
NCT05587309Erosive Esophagitis · United States3CompletedSebela PharmaceuticalsJun 16, 20251,250
NCT05577468Helicobacter Pylori Infection · China3CompletedShandong Luoxin Pharmaceutical Group StockSep 30, 2023561
NCT05353010Healthy · Korea, Republic of1UNKNOWNHK inno.NJul 1, 202212
NCT05010954Duodenal Ulcer · China3CompletedShandong Luoxin Pharmaceutical Group StockSep 28, 2022400
NCT05267743Erosive Reflux Disease · Korea, Republic of4CompletedHK inno.NMay 25, 2022218
NCT04840550Preventive Peptic Ulcer · South Korea3CompletedHK inno.NJul 1, 2025392
NCT04639804Healthy · Korea, Republic of1CompletedHK inno.NJul 26, 202060
NCT04494269Hepatic Impairment · Korea, Republic of1UNKNOWNHK inno.NJun 202328
NCT04309916Erosive Reflux Disease · Korea, Republic of4CompletedHK inno.NNov 30, 202146
NCT04231136Healthy · Korea, Republic of1CompletedHK inno.NJul 29, 202019
NCT04221321Healthy · Korea, Republic of1CompletedHK inno.NMar 12, 202032
NCT04171687Healthy · Korea, Republic of1CompletedHK inno.NFeb 7, 202036
NCT04128917Helicobacter Pylori Infection · Korea, Republic of3CompletedHK inno.NDec 21, 2020102
NCT04066257Healthy · Korea, Republic of1CompletedHK inno.NFeb 22, 201932
NCT04022096Healed Erosive Esophagitis · Korea, Republic of3CompletedHK inno.NJun 23, 2021351
NCT03863938Healthy · Korea, Republic of1CompletedHK inno.NApr 26, 201912
NCT03814642Healthy · Korea, Republic of1CompletedHK inno.NJul 22, 201925
NCT03615677Erosive Esophagitis (EE) · China3CompletedShandong Luoxin Pharmaceutical Group StockOct 18, 2019261
NCT03591653Non-Erosive Reflux Disease · China3CompletedShandong Luoxin Pharmaceutical Group StockOct 30, 2019291
NCT03530228Pharmacodynamics · Korea, Republic of1UNKNOWNHK inno.NAug 201844
NCT03498456Helicobacter Pylori Infection · Korea, Republic of3CompletedHK inno.NDec 31, 2019284
NCT03458650Healthy · China1CompletedShandong Luoxin Pharmaceutical Group StockApr 23, 201838
NCT03378284Pharmacodynamics · Korea, Republic of1CompletedHK inno.NDec 23, 201716
NCT03317223Helicobacter Pylori Infection · Korea, Republic of3CompletedHK inno.NJan 21, 2019350
NCT03043521Healthy · Korea, Republic of1CompletedHK inno.NAug 12, 201524
NCT03009760Healthy1CompletedHK inno.NApr 201616
NCT03011996Drug Interaction · Korea, Republic of1CompletedHK inno.NFeb 201760
NCT02995239Erosive Esophagitis · Korea, Republic of1CompletedHK inno.NApr 201512
NCT03006874Erosive Esophagitis · Korea, Republic of3CompletedHK inno.NMar 24, 2017302
NCT02761512Stomach Ulcer · Korea, Republic of3CompletedHK inno.NJul 26, 2018306
NCT02556021Non-Erosive Reflux Disease · Korea, Republic of3CompletedHK inno.NNov 1, 2016324
NCT02456935Erosive Esophagitis · Korea, Republic of3CompletedHK inno.NJul 2016280
NCT02052336Healthy · Korea, Republic of1CompletedHK inno.NJan 201424
NCT02028663Gastroesophageal Reflux · Korea, Republic of2CompletedHK inno.NMay 2014206
NCT01830309Healthy · Korea, Republic of1CompletedHK inno.NFeb 201324
NCT01473173Healthy · Korea, Republic of1CompletedHK inno.NAug 201259

How it is read

Names in the registry

  • “Tegoprazan”, 10 entries
  • “Tegoprazan 50 mg”, 5 entries
  • “BLI5100”, 3 entries
  • “Tegoprazan 50mg”, 3 entries
  • “CJ-12420 50mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.